A Phase 2 Trial to Evaluate the Efficacy and Safety of OCV-501 in Elderly Patients With Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2017-11-16
Target enrollment:
Participant gender:
Summary
To compare disease-free survival in patients 60 years or older with acute myeloid leukemia
(AML) who are randomly assigned to receive either OCV-501 monotherapy or placebo.